Annual Drug Patent Expirations for XIIDRA
Xiidra is a drug marketed by Novartis and is included in one NDA. It is available from two suppliers. There are fifteen patents protecting this drug.
Drug patent litigation for XIIDRA.
This drug has one hundred and seven patent family members in twenty-one countries.
The generic ingredient in XIIDRA is lifitegrast. Two suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com